{
    "clinical_study": {
        "@rank": "73800", 
        "arm_group": [
            {
                "arm_group_label": "Aripiprazole", 
                "arm_group_type": "Experimental", 
                "description": "Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks."
            }, 
            {
                "arm_group_label": "Risperidone", 
                "arm_group_type": "Active Comparator", 
                "description": "Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or\n      environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical\n      presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms),\n      response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central\n      dopaminergic neurotransmission) of both conditions. Both risperidone and aripiprazole are\n      second generation antipsychotics\uff0cbut have different pharmacological effects of antipsychotic\n      treatment.This study was designed to examine the acute efficacy, safety, and tolerability of\n      risperidone and aripiprazole for patients with MAP."
        }, 
        "brief_title": "A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Methamphetamine Dependence", 
        "detailed_description": {
            "textblock": "Methods:A Multiple-Center, Randomized, Double-Blind."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV)\n             criteria for Methamphetamine-Associated Psychosis.\n\n          2. Must sign a Information consent form.\n\n          3. Required to provide detailed address and phone number\n\n        Exclusion Criteria:\n\n          1. Serious organic disease.\n\n          2. Suicide ideation or hurt others.\n\n          3. Taking antipsychotic within two weeks before.\n\n          4. drug allergy to  Risperidone or Aripiprazole.\n\n          5. pregnancy and breastfeeding women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813643", 
            "org_study_id": "100000-068941"
        }, 
        "intervention": [
            {
                "arm_group_label": "Risperidone", 
                "description": "Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks", 
                "intervention_name": "Risperidone", 
                "intervention_type": "Drug", 
                "other_name": "Risperdal H20070057"
            }, 
            {
                "arm_group_label": "Aripiprazole", 
                "description": "Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks", 
                "intervention_name": "Aripiprazole", 
                "intervention_type": "Drug", 
                "other_name": "Aopai H20041507"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methamphetamine", 
                "Risperidone", 
                "Aripiprazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Methamphetamine-Associated Psychosis", 
            "Aripiprazole", 
            "Risperidone"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Changsha", 
                    "country": "China", 
                    "state": "Hunan", 
                    "zip": "410011"
                }, 
                "name": "The Second Xiangya Hospital of Central University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment", 
        "overall_official": {
            "affiliation": "Central South University", 
            "last_name": "Wei Hao, MD., Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "China: Ethics Committee", 
                "China: National Natural Science Foundation", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Positive and Negative Syndrome Scale", 
            "measure": "The severity of psychosis", 
            "safety_issue": "Yes", 
            "time_frame": "up to 4 weeks. participants will be followed for the duration of hospital stay"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813643"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Central South University", 
            "investigator_full_name": "Wei Hao", 
            "investigator_title": "The Second Xiangya Hospital of Cental South University", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Barnes Scale , Simpson-Angus Scale , Abnormal Involuntary Movement Scale", 
                "measure": "adverse drug reaction", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 weeks. participants will be followed for the duration of hospital"
            }, 
            {
                "description": "Clinical general rating scale", 
                "measure": "Clinical general status", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 weeks. participants will be followed for the duration of hospital stay"
            }
        ], 
        "source": "Central South University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wei Hao", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013", 
        "why_stopped": "Effects of aripiprazole was not obvious and showed adverse reaction obviously"
    }
}